Company intelligence / Profile preview
Teyi Pharmaceutical Group
Taishan City, Guangdong, Chinatczy.com.cn ↗
- Ownership
- Private
- Employees
- ~1243
- Development stage
- Commercial
01
Overview
The company markets a broad portfolio of approved traditional Chinese medicines and generics in China. Recent regulatory approval for doxycycline hydrochloride tablets was noted in 2024[2].
- Therapeutic areas
- PulmonologyEndocrinologyOtherDermatologyRheumatologyGastroenterologyCardiovascularNephrologyInfectious Diseases
- Modalities
- Small moleculeHerbal medicineBiologic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not publicly disclosed; company operates an extensive distribution network across China with over 200,000 offline pharmacies
Beyond the preview
Go deeper on Teyi Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Teyi Pharmaceutical Group.